Prime Medicine soars as Jones sees it as an acquisition target

6 hours ago 2

• Healthcare
• On the Move

CIPhotos/iStock via Getty Images

• Prime Therapeutics (NASDAQ:PRME) skyrocketed ~35% Monday after JonesTrading issued a bullish report on the company due to increased interest in gene editing in the wake of Eli Lilly's (NYSE:LLY) deal last month to pay up

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Prime Medicine soars as Jones sees it as an acquisition target